123 related articles for article (PubMed ID: 36182816)
21. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
22. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
23. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
24. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
26. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
[TBL] [Abstract][Full Text] [Related]
27. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
28. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
Tsai JH; Liau JY; Lee CH; Jeng YM
Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
[TBL] [Abstract][Full Text] [Related]
29. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
30. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
31.
Crispo F; Pietrafesa M; Condelli V; Maddalena F; Bruno G; Piscazzi A; Sgambato A; Esposito F; Landriscina M
Molecules; 2020 Aug; 25(16):. PubMed ID: 32824685
[TBL] [Abstract][Full Text] [Related]
32. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.
Jiao Y; Pawlik TM; Anders RA; Selaru FM; Streppel MM; Lucas DJ; Niknafs N; Guthrie VB; Maitra A; Argani P; Offerhaus GJA; Roa JC; Roberts LR; Gores GJ; Popescu I; Alexandrescu ST; Dima S; Fassan M; Simbolo M; Mafficini A; Capelli P; Lawlor RT; Ruzzenente A; Guglielmi A; Tortora G; de Braud F; Scarpa A; Jarnagin W; Klimstra D; Karchin R; Velculescu VE; Hruban RH; Vogelstein B; Kinzler KW; Papadopoulos N; Wood LD
Nat Genet; 2013 Dec; 45(12):1470-1473. PubMed ID: 24185509
[TBL] [Abstract][Full Text] [Related]
33. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
34. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas.
Nguyen Canh H; Takahashi K; Yamamura M; Li Z; Sato Y; Yoshimura K; Kozaka K; Tanaka M; Nakanuma Y; Harada K
Histopathology; 2021 Nov; 79(5):731-750. PubMed ID: 34018212
[TBL] [Abstract][Full Text] [Related]
35. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
36. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract][Full Text] [Related]
37. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
38. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
39. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
40. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
